469 related articles for article (PubMed ID: 33934451)
1. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
5. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
[TBL] [Abstract][Full Text] [Related]
6. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
Sottile R; Pangigadde PN; Tan T; Anichini A; Sabbatino F; Trecroci F; Favoino E; Orgiano L; Roberts J; Ferrone S; Kärre K; Colucci F; Carbone E
Eur J Immunol; 2016 Feb; 46(2):409-19. PubMed ID: 26564811
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of A20 promotes immune escape of lung adenocarcinomas.
Breitenecker K; Homolya M; Luca AC; Lang V; Trenk C; Petroczi G; Mohrherr J; Horvath J; Moritsch S; Haas L; Kurnaeva M; Eferl R; Stoiber D; Moriggl R; Bilban M; Obenauf AC; Ferran C; Dome B; Laszlo V; Győrffy B; Dezso K; Moldvay J; Casanova E; Moll HP
Sci Transl Med; 2021 Jul; 13(601):. PubMed ID: 34233950
[TBL] [Abstract][Full Text] [Related]
8. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
9. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
10. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
[TBL] [Abstract][Full Text] [Related]
11. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma.
van Duijn A; Willemsen KJ; van Uden NOP; Hoyng L; Erades S; Koster J; Luiten RM; Bakker WJ
Cancer Immunol Immunother; 2022 Mar; 71(3):529-540. PubMed ID: 34268602
[TBL] [Abstract][Full Text] [Related]
12. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
13. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
[TBL] [Abstract][Full Text] [Related]
16. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
[TBL] [Abstract][Full Text] [Related]
17. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Liu H; Kuang X; Zhang Y; Ye Y; Li J; Liang L; Xie Z; Weng L; Guo J; Li H; Ma F; Chen X; Zhao S; Su J; Yang N; Fang F; Xie Y; Tao J; Zhang J; Chen M; Peng C; Sun L; Zhang X; Liu J; Han L; Xu X; Hung MC; Chen X
Cancer Cell; 2020 Mar; 37(3):324-339.e8. PubMed ID: 32183950
[TBL] [Abstract][Full Text] [Related]
18. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
19. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
20. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]